NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies (Nasdaq: NTHI) appointed David Choi as Chief Accounting Officer effective March 13, 2026. Mr. Choi will oversee accounting, financial reporting, internal controls, and corporate governance as NeOnc advances its Phase 2 clinical programs for central nervous system cancers and expands global operations.
Mr. Choi has more than a decade of experience, previously served as Director at Blythe Global Advisors, held roles at Grant Thornton and Ernst & Young, and is a Certified Public Accountant with graduate and undergraduate degrees from University of California, Irvine.
NeOnc Technologies (Nasdaq: NTHI) announced Phase 1 dose-escalation results for oral NEO212 on March 4, 2026. The study reached MTD at 810 mg (Cohort 5) after a second dose-limiting toxicity and set the RP2D at 610 mg (Cohort 4).
The Phase 2a metastasis cohort will start at 400 mg. Early safety and tolerability were assessed, and the company reported promising early signs of anti-tumor activity in heavily pretreated GBM and brain metastasis patients. NeOnc intends to request a Type B FDA meeting and submitted required regulatory forms via eCTD.
NeOnc Technologies (Nasdaq: NTHI) will host an investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial Phase 1 dose‑escalation results from the NEO212-01 trial.
The presentation will cover safety and toxicity data, dose‑escalation observations, pharmacokinetics, and planned regulatory next steps for the oral bioconjugated temozolomide program, with participation from company management and independent Scientific Advisory Board members.
NeOnc Technologies (Nasdaq: NTHI) announced a PIPE financing dated January 30, 2026 to sell up to 2,222,222 shares and five-year warrants to buy up to 2,222,222 shares at a $9.00 exercise price and a combined purchase price of $7.20.
The offering is expected to generate gross proceeds of up to $16 million, including a $10 million lead investment from Cinctive Capital Management. Net proceeds are intended for repayment of indebtedness and for working capital and corporate purposes.
NeOnc Technologies (Nasdaq: NTHI) reported updated clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma on Dec 15, 2025. The expanded cohort totals 25 patients. Key outcomes: radiographic remission in 24% (6/25), PFS-6 of 44%, and 36% (9/25) alive ≥18 months after treatment start. The company reports no significant toxicity with chronic intranasal dosing. Responses were assessed by RANO criteria and include 1 compassionate-use case, 5 Phase 1, and 18 Phase 2a patients. Management describes the dataset as an important value-inflection point and highlights reproducibility and durability of responses.
NeOnc Technologies (Nasdaq: NTHI) announced preclinical findings from a University of Southern California collaboration showing focused ultrasound enhances NEO100’s antitumor potency across primary and metastatic brain tumor models.
Researchers used an AI-driven positive–unlabeled neural network trained on >200 molecular descriptors and a rapid magnetic 3D bioprinting NAM (US Patent 11,788,057) to predict and validate NEO100 as a leading sonodynamic agent. Validation on patient-derived organoids and spheroids — including glioblastoma, pediatric medulloblastoma, high-grade meningioma, and breast- and lung-to-brain metastases — showed markedly enhanced tumor-killing when NEO100 was combined with focused ultrasound. The results support advancing NEO100 plus focused ultrasound into future clinical trials across multiple brain tumor types.
NeOnc Technologies (NASDAQ: NTHI) reported Q3 2025 results and operational updates on Nov 14, 2025. Key items include a $50.0 million strategic partnership via NuroMENA with Quazar Investment, $2.5 million in NIH STTR grants, FDA authorization to proceed with a Phase II trial of NEO212, and completed Phase 2a topline enrollment for NEO100 with encouraging efficacy signals (21% response rate; 44% six-month PFS; 33% alive ≥18 months).
Q3 financials showed a $8.6 million net loss ($0.45/share) driven by higher G&A of $903k. Upcoming catalysts: final NEO212 Phase I dosing in Q4 2025, NEO100-01 topline data in May 2026, and near-term closing/funding of the $50M commitment.
NeOnc Technologies (Nasdaq: NTHI) announced completion of full patient enrollment in the NEO100-1 Phase 2a trial for recurrent IDH1-mutant high-grade glioma (WHO Grade III/IV) on Nov 13, 2025. The company expects a preliminary data readout from the fully enrolled cohort in approximately six months, in Q2 2026. The announcement follows previously reported positive interim data from a 24-patient cohort presented on Nov 12, 2025. Management highlighted NEO100’s intranasal delivery designed to bypass the blood-brain barrier and said the readout could further validate clinical potential and advance NeOnc’s CNS oncology strategy.
NeOnc Technologies (NASDAQ:NTHI) reported updated Phase 1/2a and compassionate-use data (cohort n=24) for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma on Nov 12, 2025. Key outcomes: a 21% radiographic response rate (5/24) confirmed by contrast-enhanced and perfusion MRI, 44% PFS‑6 (6‑month progression‑free survival), and 33% alive ≥18 months (8/24). No significant toxicity was reported with prolonged intranasal dosing. The company frames these results as exceeding historical salvage-therapy benchmarks (8% response; 21–31% PFS‑6) and potentially meaningful for durable disease control pending full enrollment and six‑month post‑enrollment readout.
NeOnc Technologies (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, November 12, 2025 at 6:00 a.m. PT / 9:00 a.m. ET (prior to market open).
Management and independent Scientific Advisory Board members will present data updates from the ongoing Phase 1/2a NEO100-1 trial and compassionate use program, covering intranasal NEO100 (high-purity perillyl alcohol) in recurrent high-grade malignant glioma patients. Presentations will highlight MRI-based radiographic responses, progression-free survival (PFS), and overall survival (OS) trends observed to date. The live webcast will be available at https://investors.neonc.com.